Lunai Bioworks Inc. said it received a notice from Nasdaq’s Listing Qualifications Staff determining that the company’s securities should be delisted. The company has appealed and secured a Nasdaq Hearings Panel hearing scheduled for March 26, 2026, which stays the delisting pending a final decision, though the company cautioned there is no assurance it will be granted continued listing or regain compliance with Nasdaq requirements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000282), on February 23, 2026, and is solely responsible for the information contained therein.
Comments